Competing interests YK has received lecture fees from AbbVie GK, Eisai Co, Chugai Pharmaceutical Co, Eli Lilly Japan K.K., Mitsubishi-Tanabe, BristolMyers K.K., Astellas Pharmaceutical, Mitsubishi Tanabe Pharma Corporation, Pfizer, Janssen, Santen, ... Annals of Rheumatic Diseases, 1 week ago
Eisai Inc. and Arena Pharmaceuticals Announce Availability of Once-Daily BELVIQ XR lorcaserin HCl Extended-Release Tablets
By a News Reporter-Staff News Editor at Pharma Business Week Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced the availability of BELVIQ XR() (lorcaserin HCl) CIV extended-release 20 mg tablets, a new once-daily dosing option that ...Pharmacy Choice, 6 days ago ARENA PHARMACEUTICALS : Eisai Inc. and Arena Pharmaceuticals Announce Availability of Once-Daily BELVIQ XR® lorcaserin HCl Extended-Release Tablets 4 Traders, 1 week ago Arena Launches Belviq XR - Why Stock Reaction Is Modest Seeking Alpha, 2 weeks ago Eisai and Arena Pharmaceuticals launches weight management tablet TradingCharts.com, 2 weeks ago
Eisai Co, Ltd launched Chocola BB Rich Ceramide (notification number B60), its first food with function claims. The product, which will be available in drug stores, pharmacies and convenience stores across Japan (and on Eisai e-tailing site), is the ...FnBnews.com, 8 hours ago EISAI : TO OFFICIALLY LAUNCH 'CHOCOLA BB RICH CERAMIDE' IN STORES NATIONWIDE 4 Traders, 6 days ago Eisai announces Phase Ib trial results of lenvatinib with pembrolizumab in selected solid tumours Drug Development Technology, 1 week ago EISAI : to Officially Launch "Chocola BB Rich Ceramide" in Stores Nationwide 4 Traders, 1 week ago
Eisai has initiated a multicentre, global, randomised phase III study that will evaluate the efficacy and safety of lenvatinib in combination with anti-PD-1 immunotherapy pembrolizumab and lenvatinib in combination with everolimus versus sunitinib ...Pharma Field, 2 weeks ago Eisai Enrols Patients in Global Phase III Trial to Evaluate First-line Kisplyx® (lenvatinib) Plus Pembrolizumab or Everolimus Versus Sunitinib in Advanced Renal Cell Carcinoma Ariva.de, 3 weeks ago Eisai enrolls patients in global phase III trial to evaluate first-line Kisplyx® (lenvatinib) plus pembrolizumab or everolimus versus sunitinib in advanced renal cell carcinoma PharmiWeb, 2 weeks ago ESMO 2016 Press Release: First Feasibility Study of the ESMO-MCBS Scale in Rare Tumour Entities ESMO, 2 weeks ago
Morphotek and Eurofarma Laboratorios S.A. Sign Exclusive Licensing Agreement for Farletuzumab in Latin America
By a News Reporter-Staff News Editor at Clinical Trials Week -- Morphotek(®), Inc., a subsidiary of Eisai Inc., announced that it signed an exclusive licensing agreement with Eurofarma Laboratorios S.A. (Eurofarma) to develop and commercialize ...4 Traders, 1 week ago Morphotek and Eurofarma Laboratórios S.A. Sign Exclusive Licensing Agreement for Farletuzumab in Latin America International Business Times, 2 weeks ago Morphotek And Sign Exclusive Licensing Agreement For Farletuzumab In Latin America BioSpace, 2 weeks ago
Researchers from Eisai Detail New Studies and Findings in the Area of Clinical Trials and Studies (Impact of perampanel on pharmacokinetics of...
Researchers from Eisai Detail New Studies and Findings in the Area of Clinical Trials and Studies (Impact of perampanel on pharmacokinetics of concomitant antiepileptics in patients with partial-onset seizures: pooled analysis of clinical trials) By ...4 Traders, 3 weeks ago T-Cell Lymphomas Therapeutics Global Clinical Trials Industry Review, H2, 2016 Before It's News, 53 minutes ago Pipeline of Depression Market Covering Therapeutics Under Development for H2 2016 Minyanville, 5 hours ago Peritoneal Cancer, Market Outlook to 2016 Before It's News, 2 days ago
Arena Pharmaceuticals, Inc. (ARNA) is a biopharmaceutical company out of San Diego that with its marketing partner Eisai launched the anti-obesity drug Belviq® and Belviq XR®. The difference between the two drugs is that Belviq XR is a once-a-day ...Equities.com, 2 days ago Why Arena Pharmaceuticals Is Finally Showing Some Signs of Life Motley Fool, 1 week ago
Eisai's Lenvima thyroid cancer drug is to be funded in Scotland, after the country's cost-effectiveness body gave it the thumbs-up a decision that prompted fresh calls for it to be made available in England. Lenvima was launched during a period ...pharmaphorum, 1 week ago
Zacks Investment Research downgraded shares of Eisai Co., Ltd (NASDAQ:ESALY) According to Zacks, Eisai Co LTD is involved in the Biotechnology and Drug Industry. Their principle activities are the manufacture and sale of pharmaceutical products.Mideast Time, 2 weeks ago Eisai Co., Ltd (ESALY) Downgraded by Zacks Investment Research Zolmax News, 2 weeks ago Eisai Co., Ltd (ESALY) Stock Rating Lowered by Zacks Investment Research WKRB News, 2 weeks ago Eisai Co., Ltd. - Product Pipeline Review - 2016 Global Information Inc, 1 month ago
Current Partnering Eisai Partnering Deals and Alliances 2010 to 2016 The Partnering Deals and Alliance since 2010 report provides an in-depth insight into the partnering activity of one of the world's leading life sciences companies. On ...MarketResearch.com, 2 weeks ago
on your WebpageAdd Widget >Get your members hooked!